Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
US10829473B2 · kind B2 · utility
0Cited by
1References
2Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | May 19, 2020 |
| Grant date | Nov 10, 2020 |
| Priority date | — |
| Expiry date | May 19, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D471/04
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The invention discloses compounds of Formula (I), wherein A1, R1, R2, R3, R4, and n are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.